免疫检查点抑制剂致免疫相关肝损伤的研究进展

Research progress in immune-related liver injury caused by immune checkpoint inhibitors

近年来,免疫检查点抑制剂(ICIs)在肿瘤患者的治疗中取得了很大进展,延长了患者的生存期。然而,在其增强免疫抗肿瘤的同时也可能造成免疫耐受失衡从而导致不同程度的免疫相关不良事件(irAEs)发生,ICIs致免疫相关肝损伤(ILICI)是其中较为常见的一种。主要对ILICI的定义、流行病学及危险因素、发病机制、病理及临床表现、治疗、复发及再治疗的研究进展进行综述。

In recent years,immune checkpoint inhibitors(ICIs)have made great progress in the treatment of tumor patients,prolonging their survival.However,the expansion of immunity against tumors with ICIs may also cause an imbalance in immune tolerance,leading to immune-related adverse events(irAEs).Immune-mediated liver injury caused by ICIs(ILICI)is one of the more common types of irAEs.In this review paper,the definition,epidemiology,risk factors,pathogenesis,pathology,clinical manifestations,treatment,recurrence,and re-treatment of ILICI were summarized to provide a basis for clinical diagnosis and treatment.